Adenocarcinoma

• 

  Subject Areas on Research

  • "Tips" on acute arthritis and clubbing. 
  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. 
  • 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. 
  • 1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET. 
  • 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. 
  • A 10-gene progenitor cell signature predicts poor prognosis in lung adenocarcinoma. 
  • A 3D Poly(ethylene glycol)-based Tumor Angiogenesis Model to Study the Influence of Vascular Cells on Lung Tumor Cell Behavior. 
  • A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. 
  • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 
  • A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. 
  • A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. 
  • A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. 
  • A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. 
  • A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. 
  • A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. 
  • A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. 
  • A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen. 
  • A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiated-Type Intramucosal Gastric Cancer. 
  • A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. 
  • A comparison of laparoscopically assisted and open colectomy for colon cancer. 
  • A comparison using tissue electrical properties and temperature rise to determine relative absorption of microwave power in malignant tissue. 
  • A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. 
  • A histopathologic study of retinal arterial aneurysms. 
  • A hypothetic mechanism of diethylstilbestrol(DES)-induced anomalies in exposed progeny. 
  • A matched case-control study of preoperative biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified. 
  • A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. 
  • A multiple testing procedure to associate gene expression levels with survival. 
  • A new assay to quantify in vivo repair of G:T mispairs by base excision repair. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. 
  • A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. 
  • A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. 
  • A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. 
  • A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. 
  • A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. 
  • A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. 
  • A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. 
  • A phase I/II study of intraoperative radiotherapy in advanced unresectable or recurrent carcinoma of the rectum: a Radiation Therapy Oncology Group (RTOG) study. 
  • A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. 
  • A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. 
  • A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. 
  • A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. 
  • A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. 
  • A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. 
  • A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. 
  • A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. 
  • A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. 
  • A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. 
  • A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. 
  • A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. 
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. 
  • A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. 
  • A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. 
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. 
  • A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions. 
  • A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 
  • A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. 
  • A rare case of metastatic extramammary Paget disease of the spine and review of the literature. 
  • A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. 
  • A single genetic locus determines the efficacy of serum therapy against murine adenocarcinoma 755a. 
  • A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. 
  • A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. 
  • A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. 
  • A statistic for comparing two correlated markers which are prognostic for time to an event. 
  • A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. 
  • A systematic review on sinonasal mixed adenoneuroendocrine carcinoma. 
  • A transgenic mouse prostate cancer model. 
  • A trial of prophylactic cefamandole in extended gynecologic surgery. 
  • A unique tripartite collision tumor of the esophagus: A case report. 
  • ACR Appropriateness Criteria® Pancreatic Cyst. 
  • ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. 
  • ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. 
  • Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation. 
  • Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. 
  • Ablative therapies for Barrett's esophagus. 
  • Abnormal monocyte chemotaxis in patients with breast cancer: evidence for a tumor-mediated effect. 
  • Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma. 
  • Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. 
  • Accessory parotid glands as a site of metastases from outside the head and neck: case report. 
  • Acoustic radiation force impulse (ARFI) imaging of the gastrointestinal tract. 
  • Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. 
  • Acute urinary retention associated with prostatic carcinoma. 
  • Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. 
  • Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. 
  • Adenocarcinoma arising in a diverticulum of the female urethra. 
  • Adenocarcinoma of Pigmented Ciliary Epithelium in a Child With Aicardi Syndrome and Congenital Microphthalmia With Cyst. 
  • Adenocarcinoma of the kidney. II. Enzyme histochemistry of renal adenocarcinomas induced in rats by N-(4'-fluoro-4-biphenylyl)acetamide. 
  • Adenocarcinoma of the liver without a detectable primary. 
  • Adenocarcinoma of the prostate. I. Tissue sampling considerations. 
  • Adenocarcinoma of the prostate. Part II: Tissue prognosticators. 
  • Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. 
  • Adenocarcinoma of the prostate: stage A1. 
  • Adenocarcinoma of the retinal pigment epithelium: a diagnostic and therapeutic challenge. 
  • Adenocarcinoma of the stomach. Changing patterns over the last 4 decades. 
  • Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. 
  • Adenosis and clear-cell carcinoma of the vagina. An invitational sympotium. Introduction. 
  • Adenosquamous differentiation: mammary needle aspiration cytology. 
  • Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. 
  • Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. 
  • Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). 
  • Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer. 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adjuvant postoperative radiation therapy for rectal adenocarcinoma. 
  • Adjuvant radiation therapy for distal pancreatic cancer: is there a role? 
  • Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. 
  • Adjuvant therapy for surgically resected pancreatic adenocarcinoma. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. 
  • Adrenal insufficiency secondary to metastatic lung carcinoma: CT aided diagnosis. 
  • Adult intussusception secondary to colorectal cancer in a young man: a case report. 
  • Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. 
  • Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. 
  • Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. 
  • Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer. 
  • Age-incidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix. 
  • Allergies, obesity, other risk factors and survival from pancreatic cancer. 
  • Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. 
  • Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. 
  • Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene. 
  • American Gastroenterological Association Institute and College of American Pathologists Quality Measure Development for Detection of Mismatch Repair Deficiency and Lynch Syndrome Management. 
  • Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. 
  • An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. 
  • An unusual cause of cholecystitis? 
  • Anal cancer: an overview. 
  • Analysis of factors associated with the tumorigenic potential of 12 tumor clones derived from a single rat colon adenocarcinoma. 
  • Analysis of oxygen transport to tumor tissue by microvascular networks. 
  • Analysis of prognostic variables which influence early and long-term response of pet animal tumors to radiation alone and radiation plus heat. 
  • Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. 
  • Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. 
  • Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. 
  • Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 
  • Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. 
  • Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. 
  • Androgen-independent prostate cancer progression in the TRAMP model. 
  • Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. 
  • Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. 
  • Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. 
  • Antemortem diagnosis of an endomyocardial breast cancer metastasis by transvenous endomyocardial biopsy. 
  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). 
  • Antidiabetic therapies affect risk of pancreatic cancer. 
  • Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. 
  • Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. 
  • Anuria resulting from extrinsic ureteral compression. 
  • Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. 
  • Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. 
  • Assessment of advanced gastric cancer management in the United States. 
  • Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. 
  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. 
  • Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. 
  • Association between hepatitis B virus and pancreatic cancer. 
  • Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. 
  • Association between polymorphisms in the GSTA4 gene and risk of lung cancer: a case-control study in a Southeastern Chinese population. 
  • Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. 
  • Association of diabetes and perineural invasion in pancreatic cancer. 
  • Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. 
  • Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. 
  • Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. 
  • Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. 
  • Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. 
  • Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. 
  • BK virus-associated urinary bladder carcinoma in transplant recipients: productive or nonproductive polyomavirus infections in tumor cells? 
  • BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. 
  • Barrett's esophagus in 2008: an update. 
  • Bcl-2 accelerates multistep prostate carcinogenesis in vivo. 
  • Benign adrenal lesions mimicking malignancy on MR imaging: report of two cases. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. 
  • Bilateral pelvic lymph node metastases in a case of FIGO stage IA(1) adenocarcinoma of the cervix. 
  • Bilateral renal carcinoma in von Hippel-Lindau Disease. 
  • Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy. 
  • Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. 
  • Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. 
  • Black tea consumption and risk of rectal cancer in Moscow population. 
  • Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. 
  • Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. 
  • Breast biopsy in women 30 years old or less. 
  • Breast carcinoma masquerading as primary ovarian neoplasm. 
  • Breast carcinoma, thyroid carcinoma, and T3 thyrotoxicosis in a male cretin. 
  • Breast reconstruction following mastectomy. 
  • Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. 
  • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. 
  • CD8(+)NKR-P1A (+)T cells preferentially accumulate in human liver. 
  • CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables. 
  • CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. 
  • CT of intracardiac tumor. 
  • CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. 
  • CT-derived body composition measurements as predictors for neoadjuvant treatment tolerance and survival in gastroesophageal adenocarcinoma. 
  • Ca(2+)-dependent nitric oxide release in endothelial but not R3230Ac rat mammary adenocarcinoma cells. 
  • Cadmium-induced neoplastic transformation of human prostate epithelial cells. 
  • Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. 
  • Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? 
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Carbonic anhydrase IX in early-stage non-small cell lung cancer. 
  • Carcinogen 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis is accelerated in Smad3 heterozygous mice compared to Smad3 wild type mice. 
  • Carcinogenesis in urogenital sites. 
  • Carcinoid tumors of the appendix: are these tumors identifiable prospectively on preoperative CT? 
  • Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. 
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. 
  • Carcinoma of the lung in the absence of asbestosis: The value of lung fiber burden analysis. 
  • Carcinoma of the lung with osseous stromal metaplasia. 
  • Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. 
  • Carcinoma of the prostate: the therapeutic dilemma. 
  • Carcinoma of unknown primary: natural history and response to therapy. 
  • Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. 
  • Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. 
  • Case report. Intrabiliary colonic metastasis mimicking primary biliary neoplasia. 
  • Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. 
  • Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). 
  • Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. 
  • Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. 
  • Ceruminous gland adenocarcinoma: a light and electron microscopic study. 
  • Cervical cancer. 
  • Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. 
  • Cervical screening and general physical examination behaviors of women exposed in utero to diethylstilbestrol. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma. 
  • Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. 
  • Changing trends in the proportions of small (≤ 2 cm) proximal and non-proximal gastric carcinomas treated at a high-volume tertiary medical center in China. 
  • Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. 
  • Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. 
  • Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. 
  • Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 
  • Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. 
  • Chemoradiation for localized pancreatic cancer: another perspective. 
  • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 
  • Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. 
  • Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 
  • Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. 
  • Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. 
  • Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS). 
  • Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. 
  • Clear cell adenocarcinoma of the vagina and cervix: incidence, undetected disease, and diethylstilbestrol. 
  • Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases. 
  • Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy. 
  • Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. 
  • Clinical and pathologic correlates in surgical stage II endometrial carcinoma. 
  • Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. 
  • Clinical application of a 3D ultrasound-guided prostate biopsy system. 
  • Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 
  • Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. 
  • Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man. 
  • Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. 
  • Clonality of combined tumors. 
  • Clustered cancer cells show a distinct adhesion behavior from single cell form under physiological shear conditions. 
  • Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis. 
  • Collision tumour of the ampulla of Vater: carcinoid and adenocarcinoma. 
  • Colonoscopic injection for murine solid cecal cancer model. 
  • Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. 
  • Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. 
  • Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). 
  • Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. 
  • Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. 
  • Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. 
  • Commentary: Admission is not absolution-The burden of proof remains. 
  • Commentary: You can't hit what you can't see: Esophageal adenocarcinoma with signet ring cells. 
  • Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. 
  • Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma. 
  • Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. 
  • Comparison of animal models for head and neck cancer cachexia. 
  • Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. 
  • Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. 
  • Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. 
  • Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. 
  • Complete pathologic response after chemoradiation for rectal cancer. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Complications of prenatal therapy with diethylstilbestrol. 
  • Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. 
  • Comprehensive molecular characterization of gastric adenocarcinoma. 
  • Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. 
  • Computed tomographic imaging of microscopic dystrophic calcification in urachal adenocarcinoma. 
  • Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation. 
  • Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology. 
  • Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. 
  • Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. 
  • Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. 
  • Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. 
  • Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. 
  • Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. 
  • Controlled aspiration of subretinal fluid in the diagnosis of carcinoma metastatic to the choroid. 
  • Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. 
  • Correlation of DNA ploidy and histologic diagnosis from prostate core-needle biopsies: is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens? 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. 
  • Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis. 
  • Current perspectives on locally advanced pancreatic cancer. 
  • Cyclocreatine in cancer chemotherapy. 
  • Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. 
  • Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report. 
  • Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients. 
  • Cytologic features of adenocarcinoma, not otherwise specified, in conventional smears: comparison of cases that performed poorly with those that performed well in the College of American Pathologists Interlaboratory Comparison Program in cervicovaginal cytology. 
  • Cytologically low grade malignancies: an important interpretative pitfall responsible for false negative diagnoses in fine-needle aspiration of the breast. 
  • Cytology of clear-cell adenocarcinoma of genital tract in young females: review of 95 cases from the registry. 
  • Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis. 
  • D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. 
  • DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 
  • DNA in radical prostatectomy specimens. Prognostic value of tumor ploidy. 
  • DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. 
  • DOK2 inhibits EGFR-mutated lung adenocarcinoma. 
  • DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. 
  • Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. 
  • Deep-tissue photoacoustic tomography of a genetically encoded near-infrared fluorescent probe. 
  • Defective monocyte function in patients with genitourinary carcinoma. 
  • Defining surgical indications for type I gastric carcinoid tumor. 
  • Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. 
  • Delay in Adjuvant Chemotherapy and Survival Advantage in Stage III Colon Cancer. 
  • Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? 
  • Delivery-corrected imaging of fluorescently-labeled glucose reveals distinct metabolic phenotypes in murine breast cancer. 
  • Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. 
  • Depression of murine macrophage accumulation by low-molecular-weight derived from spontaneous mammary carcinomas. 
  • Depth of Muscularis Propria Invasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma. 
  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 
  • Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy. 
  • Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. 
  • Detection of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)-DNA adducts in human pancreatic tissues. 
  • Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. 
  • Detection of dysplasia in Barrett's esophagus with in vivo depth-resolved nuclear morphology measurements. 
  • Detection of early-stage pancreatic adenocarcinoma. 
  • Detection of intestinal dysplasia using angle-resolved low coherence interferometry. 
  • Detection of metastatic tumors in nude mice: brief communication. 
  • Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction. 
  • Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). 
  • Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. 
  • Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. 
  • Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells. 
  • Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. 
  • Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy. 
  • Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. 
  • Diagnosis and treatment of primary extrahepatic bile duct tumors. 
  • Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. 
  • Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 
  • Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 
  • Diagnosis of pancreatic carcinoma: role of FDG PET. 
  • Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. 
  • Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution. 
  • Differences in leucocyte-endothelium interactions between normal and adenocarcinoma bearing tissues in response to radiation. 
  • Differential adhesion of rat colon carcinoma cells to fibronectin in relation to their tumorigenicity. 
  • Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. 
  • Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. 
  • Diminished leukocyte-endothelium interaction in tumor microvessels. 
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 
  • Direct invasion of the transverse colon by a cecal tumor. 
  • Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. 
  • Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. 
  • Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. 
  • Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient? 
  • Distal pancreatectomy: a single institution's experience in open, laparoscopic, and robotic approaches. 
  • Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 
  • Distribution of integrin cell adhesion molecules in endometrial cancer. 
  • Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. 
  • Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance? 
  • Do the results of systematic biopsies predict outcome in patients with T1-T2 prostate cancer treated with radiation therapy alone? 
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. 
  • Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. 
  • Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? 
  • Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? 
  • Does the interval of screening endoscopy affect survival in gastric cancer patients?: A cross-sectional study. 
  • Does transurethral resection of the prostate promote metastatic disease? 
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 
  • Double Negativity for Expression of YAP1 and CDX2 Defines an Aggressive Type of Colitis-associated Cancer. 
  • Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. 
  • Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. 
  • Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. 
  • Drivers of Esophageal Adenocarcinoma and Opportunities for Cancer Interception. 
  • Ductal metaplasia in oesophageal submucosal glands is associated with inflammation and oesophageal adenocarcinoma. 
  • Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. 
  • Duodenocolic fistula due to adenocarcinoma of the pancreas. 
  • Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma. 
  • Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma. 
  • Dysplasia and cytologic findings in 4,589 young women enrolled in diethylstilbestrol-adenosis (DESAD) project. 
  • E-cadherin in gastric carcinomas: Relations with histological parameters and its prognostic value. 
  • EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. 
  • EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance? 
  • ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. 
  • Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. 
  • Early onset baldness and prostate cancer risk. 
  • Early onset of spontaneous renal preneoplastic and neoplastic lesions in young conventional rats in toxicity studies. 
  • Early onset pancreatic malignancies: Clinical characteristics and survival associations. 
  • Early results with combined modality therapy for carcinoma of the esophagus. 
  • Ectopic expression of mucins in colorectal cancer metastasis. 
  • Editorial comment. 
  • Editorial: Problems in the examination of the DES-exposed female. 
  • Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. 
  • Effect of exposure to light-at-night on life span and spontaneous carcinogenesis in female CBA mice. 
  • Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. 
  • Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. 
  • Effect of intra-operative fluid volume on peri-operative outcomes after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. 
  • Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. 
  • Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. 
  • Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma. 
  • Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid. 
  • Effective surgical adjuvant therapy for high-risk rectal carcinoma. 
  • Effects of bradykinin on the hemodynamics of tumor and granulating normal tissue microvasculature. 
  • Effects of long-term estrogen replacement therapy. I. Metabolic effects. 
  • Effects of long-term estrogen replacement therapy. II. Neoplasia. 
  • Effects of the calcium channel blocker flunarizine on the hemodynamics and oxygenation of tumor microvasculature. 
  • Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. 
  • Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. 
  • Electrophoretic analysis of four high molecular weight sialoglycoproteins produced by metastatic human colon carcinoma cells. 
  • Endobronchial metastatic breast cancer with pagetoid histology mimicking bronchial pagetoid squamous cell carcinoma in situ. 
  • Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of "Copy-number Low" Tumors. 
  • Endometrioid carcinoma of the endometrium with sertoliform differentiation. 
  • Endoscopic ultrasound-guided fine needle aspiration biopsy of the intrapancreatic accessory spleen: a report of 2 cases. 
  • Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide. 
  • Enhancer-derived long non-coding RNAs CCAT1 and CCAT2 at rs6983267 has limited predictability for early stage colorectal carcinoma metastasis. 
  • Enteric type adenocarcinoma of the upper tract urothelium associated with ectopic ureter and renal dysplasia: an oncological rationale for complete extirpation of this aberrant developmental anomaly. 
  • Environmental tobacco smoke and lung cancer risk in nonsmoking women. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Eosinophilic intracytoplasmic globules in pulmonary adenocarcinomas: a histochemical, immunohistochemical, and ultrastructural study of six cases. 
  • Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. 
  • Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. 
  • Epidermal growth factor receptor expression in normal and malignant endometrium. 
  • Epidermal growth factor receptor gene analysis in renal cell carcinoma. 
  • Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. 
  • Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. 
  • Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. 
  • Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. 
  • Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. 
  • Esophageal adenocarcinoma in a patient with surgically treated achalasia. 
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. 
  • Esophageal and esophagogastric junction cancers. 
  • Esophageal submucosal glands as a potential source of subsquamous intestinal metaplasia in Barrett's esophagus. 
  • Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). 
  • Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). 
  • Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival. 
  • Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. 
  • Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. 
  • Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. 
  • Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? 
  • Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. 
  • Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. 
  • Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. 
  • Evaluation of squamous epithelium in adenoacanthoma and adenosquamous carcinoma of the endometrium: immunoperoxidase analysis of involucrin and keratin localization. 
  • Evaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison study. 
  • Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. 
  • Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. 
  • Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. 
  • Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. 
  • Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen. 
  • Evolving application of minimally invasive cancer operations at a tertiary cancer center. 
  • Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. 
  • Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. 
  • Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. 
  • Experience with Gleason's histopathologic grading in prostatic cancer. 
  • Experimental method for the hyperthermic treatment of cells in tissue culture: initial application to pancreatic cancer cells. 
  • Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus. 
  • Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. 
  • Expression of major histocompatibility complex class I antigens in normal and transformed rat thyroid epithelial cell lines. 
  • Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. 
  • Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. 
  • Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. 
  • Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. 
  • Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma. 
  • Extended hepatic resection for gallbladder cancer. 
  • Extended resection for pancreatic adenocarcinoma. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • F-18 FDG PET/CT imaging of a hidradenocarcinoma of head and neck. 
  • FDG-PET in the selection of brain lesions for biopsy. 
  • Factors associated with a lack of pap smear utilization in women exposed in utero to diethylstilbestrol. 
  • Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. 
  • Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma. 
  • Familial pancreatic cancer. 
  • Feasibility and yield of screening in relatives from familial pancreatic cancer families. 
  • Feasibility of flap reconstruction in conjunction with intraoperative radiation therapy for advanced and recurrent head and neck cancer. 
  • Feeding jejunostomy tube placement in patients undergoing pancreaticoduodenectomy: an ongoing dilemma. 
  • Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. 
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). 
  • Fifty years of pancreas cancer care. 
  • Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. 
  • Fine-needle aspiration of inflammatory carcinoma of the breast. 
  • First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. 
  • Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer. 
  • Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. 
  • Flow cytometry as a predictive indicator in patients with operable gastric cancer. 
  • Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. 
  • Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. 
  • Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. 
  • Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. 
  • Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. 
  • Follicular thyroid carcinoma metastatic to the iris: a solitary lesion treated with iridocyclectomy. 
  • Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. 
  • Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. 
  • Functional airway obstruction observed with hyperpolarized 129 Xenon-MRI. 
  • Functional expression of sodium-glucose transporters in cancer. 
  • GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. 
  • Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. 
  • Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. 
  • Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Gastric adenocarcinoma associated with gastritis cystica profunda in an unoperated stomach. 
  • Gastric adenocarcinoma: CT versus surgical staging. 
  • Gastric cancer: an infectious disease. 
  • Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplication. 
  • Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. 
  • Generalized cutaneous metastases from breast adenocarcinoma. 
  • Genetic alterations in prostate adenocarcinoma. 
  • Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. 
  • Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. 
  • Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. 
  • Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. 
  • Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population. 
  • Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population. 
  • Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. 
  • Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas. 
  • Genomic profiles specific to patient ethnicity in lung adenocarcinoma. 
  • Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. 
  • Glassy cell carcinoma of the cervix. 
  • Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. 
  • Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. 
  • Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. 
  • Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. 
  • Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11. 
  • Growth kinetics of human colorectal carcinoma. 
  • Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 
  • HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. 
  • HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. 
  • Hepatic adenoma and focal nodular hyperplasia. 
  • Hepatic resection for metastatic cancer. 
  • Heterogeneity in the hormonal responsiveness of clones derived from the 13762NF rat mammary tumor. 
  • Heterogeneity in tumor microvascular response to radiation. 
  • Heterogeneity of antigen expression in advanced epithelial ovarian cancer. 
  • Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. 
  • Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. 
  • High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. 
  • High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. 
  • High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. 
  • High success rate of repeat colonoscopy with standard endoscopes in patients referred for prior incomplete colonoscopy. 
  • High yield reproducible rat model recapitulating human Barrett's carcinogenesis. 
  • High-LET Radiation Increases Tumor Progression in a K-Ras-Driven Model of Lung Adenocarcinoma. 
  • High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. 
  • High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. 
  • High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. 
  • High-grade dysplasia of the cystic duct margin in the absence of malignancy after cholecystectomy. 
  • High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. 
  • Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison. 
  • Histologic grading as predictor of response to chemotherapy in patients with prostatic adenocarcinoma. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. 
  • Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. 
  • How good is screening for colorectal cancer? 
  • How the radiologist can add value in the evaluation of the pre- and post-surgical pancreas. 
  • How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. 
  • Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia. 
  • Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. 
  • Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. 
  • Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. 
  • Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. 
  • Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. 
  • Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. 
  • Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. 
  • IGF2R genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites. 
  • IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. 
  • Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. 
  • Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. 
  • Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. 
  • Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). 
  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. 
  • Images in clinical medicine. Rapid progression of basal-type breast cancer. 
  • Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. 
  • Immune signatures predict prognosis in localized cancer. 
  • Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: correlation with p16(INK4a) expression. 
  • Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. 
  • Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. 
  • Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells. 
  • Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A. 
  • Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus. 
  • Immunologic control of the ascites of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells. 
  • Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. 
  • Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. 
  • Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer. 
  • Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. 
  • Impact of Time to Endoscopic Resection on Outcomes for Stage I Esophageal Adenocarcinoma. 
  • Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. 
  • Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma. 
  • Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. 
  • Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Impact of pelvic lymphadenectomy in patients with prostatic adenocarcinoma. 
  • Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • Impact of radical prostatectomy in the management of clinically localized disease. 
  • Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. 
  • Importance of routine vascular nephrotomography in excretory urography. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns. 
  • In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. 
  • In vitro chemotherapeutic testing of urologic tumors. 
  • In vivo cancer diagnosis of the esophagus using differential normalized fluorescence (DNF) indices. 
  • In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. 
  • Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. 
  • Incidental, subsolid pulmonary nodules at CT: etiology and management. 
  • Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? 
  • Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. 
  • Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin-sulfate monoclonal antibody. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. 
  • Indications for and the technique of local resection of tumors of the papilla of Vater. 
  • Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. 
  • Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. 
  • Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration. 
  • Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53. 
  • Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. 
  • Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 
  • Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. 
  • Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. 
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. 
  • Insurance Status, Not Race, is Associated With Use of Minimally Invasive Surgical Approach for Rectal Cancer. 
  • Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. 
  • Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. 
  • Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. 
  • Integrated genomic characterization of oesophageal carcinoma. 
  • Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. 
  • Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. 
  • Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. 
  • Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. 
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. 
  • Intensity-modulated radiotherapy optimization with gEUD-guided dose-volume objectives. 
  • Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. 
  • Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release. 
  • Intercellular junctions and tumor behavior in lung cancer. 
  • Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. 
  • International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 
  • Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. 
  • Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. 
  • Intraoperatic electron beam irradiation in pancreatic cancer. 
  • Intraoperative fluid management and complications following pancreatectomy. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. 
  • Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. 
  • Intratumoral inflammation is associated with more aggressive prostate cancer. 
  • Intrauterine diethylstilbestrol exposure and its consequences: pathologic characteristics of vaginal adenosis, clear cell adenocarcinoma, and related lesions. 
  • Invited Commentary: Clinical Assessment of Pediatric Patients with Differentiated Thyroid Carcinoma: A 30-Year Experience at the Single Institution. 
  • Invited commentary. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? 
  • Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. 
  • Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma? 
  • Isolation of a human prostate carcinoma cell line (DU 145). 
  • K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. 
  • Kinetics of liver volume changes in the first year after portal vein embolization. 
  • LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia. 
  • LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. 
  • Lack of effects from 2000-Hz magnetic fields on mammary adenocarcinoma and reproductive hormones in rats 
  • Laparoscopic distal pancreatectomy: evolution of a technique at a single institution. 
  • Laparoscopic intestinal stomas. 
  • Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. 
  • Late intrascrotal metastases from renal cell carcinoma. 
  • Ligand-specific dynamics of the androgen receptor at its response element in living cells. 
  • Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. 
  • Liver and prostate adenocarcinoma: an "estrogen-free" environment? 
  • Local 42 degrees C hyperthermia improves vascular conductance of the R3230Ac rat mammary adenocarcinoma during sodium nitroprusside infusion. 
  • Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. 
  • Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. 
  • Local failure following curative resection of colonic adenocarcinoma. 
  • Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. 
  • Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. 
  • Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). 
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. 
  • Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. 
  • Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. 
  • Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. 
  • Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. 
  • Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. 
  • Low-carbohydrate diets and prostate cancer: how low is "low enough"? 
  • Low-dose preoperative radiation therapy for adenocarcinoma of the endometrium. A pilot study. 
  • Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. 
  • Lung cancer in Florida. Risks associated with residence in the central Florida phosphate mining region. 
  • Lung cancer in women. 
  • Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. 
  • Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. 
  • Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. 
  • MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. 
  • Magnetic resonance imaging of the pancreas with gadolinium-DTPA. 
  • Magnetic resonance spectroscopic studies of the prostate. 
  • Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. 
  • Male breast cancer during treatment with leuprolide for prostate cancer. 
  • Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. 
  • Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. 
  • Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Management of metastatic prostatic cancer. 
  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 
  • Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. 
  • Massive locally extensive prostate cancer. 
  • Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. 
  • Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. 
  • Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. 
  • Medical malpractice and prostate brachytherapy. 
  • Mesothelioma vs. adenocarcinoma. 
  • Metastasis dynamics for non-small-cell lung cancer: effect of patient and tumor-related factors. 
  • Metastatic adenocarcinoma to the neck from an unknown primary source. 
  • Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. 
  • Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report. 
  • Metastatic carcinoma of the iris. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • Metastatic human breast cancer to the spine produces mechanical hyperalgesia and gait deficits in rodents. 
  • Metastatic patterns in adenocarcinoma. 
  • Metastatic potential of colon carcinoma. Expression of ABO/Lewis-related antigens. 
  • Metastatic prostate cancer in a transgenic mouse. 
  • Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. 
  • MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model. 
  • Microglandular hyperplasia in vaginal adenosis associated with oral contraceptives and prenatal diethylstilbestrol exposure. 
  • Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. 
  • Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. 
  • Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine. 
  • Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. 
  • Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. 
  • Microwave power absorption differences between normal and malignant tissue. 
  • Minimally Invasive Distal Pancreatectomy for Cancer: Short-Term Oncologic Outcomes in 1,733 Patients. 
  • Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. 
  • Minimally Invasive Versus Open Low Anterior Resection: Equivalent Survival in a National Analysis of 14,033 Patients With Rectal Cancer. 
  • Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. 
  • Minimally invasive gastrectomy for gastric cancer: A national perspective on oncologic outcomes and overall survival. 
  • Mitochondrial DNA alterations in thyroid cancer. 
  • Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gallbladder: A Systematic Review of Outcomes Following Surgical Management. 
  • Mixed Adenoneuroendocrine Carcinoma, Amphicrine Type, of the Small Bowel. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Modulation of implantation-associated integrin expression but not uteroglobin by steroid hormones in an endometrial cell line. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Molecular MRI for sensitive and specific detection of lung metastases. 
  • Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. 
  • Molecular biologic staging of esophageal cancer. 
  • Molecular biology of esophageal cancer. 
  • Molecular characterization of adenocarcinoma of the cervix. 
  • Molecular classification and molecular genetics of human lung cancers. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. 
  • Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. 
  • Monocyte chemotactic mechanisms in patients with hypernephroma. 
  • Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review. 
  • Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. 
  • Morphologic and immunologic studies of human prostatic carcinoma. 
  • Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. 
  • Mouse models of metastatic pancreatic adenocarcinoma. 
  • Muir-Torre syndrome. 
  • Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. 
  • Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. 
  • Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. 
  • Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature. 
  • Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer. 
  • Multimodal therapy of prostatic cancer. 
  • Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • N-terminal 1-54 amino acid sequence and Armadillo repeat domain are indispensable for P120-catenin isoform 1A in regulating E-cadherin. 
  • NCCN Clinical Practice Guidelines Occult primary. 
  • NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. 
  • Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. 
  • Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. 
  • Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. 
  • Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. 
  • Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. 
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. 
  • Neoplasia of the colon: a late complication of ureterosigmoidostomy. 
  • Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. 
  • Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms. 
  • Neuroendocrine differentiation of prostate cancer. 
  • Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. 
  • Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. 
  • New NCCN Guidelines for Locally Advanced Pancreatic Cancer: New Horizons in Extending Resectability. 
  • New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes. 
  • New option for the initial management of metastatic pancreatic cancer? 
  • Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. 
  • Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. 
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 
  • No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. 
  • Nodular regenerative hyperplasia in partial hepatectomy specimens. 
  • Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. 
  • Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. 
  • Nonoperative management of rectal cancer: current perspectives. 
  • Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. 
  • Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Novel therapeutic approaches to advanced prostate cancer. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Nuclear DNA content of clear cell adenocarcinoma of the vagina and cervix and its relationship to prognosis. 
  • Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. 
  • Obliteration of the fat surrounding the celiac axis and superior mesenteric artery is not a specific CT finding of carcinoma of the pancreas. 
  • Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. 
  • Obstructive and perforative colonic carcinoma: patterns of failure. 
  • Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. 
  • Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. 
  • Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. 
  • Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. 
  • Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. 
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. 
  • Orbital phlebography in the study of cavernous sinus disease. 
  • Osteopontin has a protective role in prostate tumor development in mice. 
  • Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. 
  • Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. 
  • Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. 
  • Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. 
  • Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy. 
  • Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. 
  • Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. 
  • Overexpression and mutation of p53 in endometrial carcinoma. 
  • Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. 
  • Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. 
  • Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. 
  • Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. 
  • Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. 
  • Overexpression of synuclein-gamma in pancreatic adenocarcinoma. 
  • Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. 
  • Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. 
  • Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. 
  • Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. 
  • PC3 is a cell line characteristic of prostatic small cell carcinoma. 
  • PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. 
  • PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. 
  • PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer. 
  • PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. 
  • PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. 
  • PTEN/MMAC1 mutations in endometrial cancers. 
  • Pain and depression in patients with newly diagnosed pancreas cancer. 
  • Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. 
  • Pancreatic Adenocarcinoma, Version 1.2019. 
  • Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. 
  • Pancreatic FNA in 1000 cases: a comparison of imaging modalities. 
  • Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. 
  • Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. 
  • Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. 
  • Pancreatic adenocarcinoma. 
  • Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: putting a hump in survival. 
  • Pancreatic adenocarcinoma: the actual 5-year survivors. 
  • Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts. 
  • Pancreatic panniculitis. 
  • Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody. 
  • Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. 
  • Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. 
  • Pathogenesis and Cells of Origin of Barrett's Esophagus. 
  • Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. 
  • Pathologic Factors Affecting Colorectal Cancer Survival in a Jamaican Population-the UHWI Experience. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Pathologic findings in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) project. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Pathology of prenatal diethylstilbestrol exposure. 
  • Pathology of vaginal and cervical abnormalities associated with prenatal exposure to diethylstilbestrol (des). 
  • Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. 
  • Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. 
  • Patterns of Care in Neoadjuvant Chemoradiotherapy for Node-Positive Esophageal Adenocarcinoma. 
  • Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer. 
  • Patterns of care study decision tree and management guidelines for esophageal cancer. American College of Radiology. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990. 
  • Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma. 
  • Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. 
  • Patterns of recurrence after trimodality therapy for esophageal cancer. 
  • Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. 
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. 
  • Percutaneous biopsy of periarterial soft tissue cuffs in the diagnosis of pancreatic carcinoma. 
  • Perfusion of single tumor microvessels: application to vascular permeability measurement. 
  • Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. 
  • Peritoneal cytology and invasive carcinoma of the cervix. 
  • Persistent Pure Ground-Glass Nodules Larger Than 5 mm: Differentiation of Invasive Pulmonary Adenocarcinomas From Preinvasive Lesions or Minimally Invasive Adenocarcinomas Using Texture Analysis. 
  • Persistent pulmonary subsolid nodules with solid portions of 5 mm or smaller: Their natural course and predictors of interval growth. 
  • Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. 
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 
  • Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. 
  • Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. 
  • Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Phase I study of recombinant human endostatin in patients with advanced solid tumors. 
  • Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. 
  • Phase I trial of interleukin-2 plus gamma-interferon. 
  • Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer. 
  • Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial. 
  • Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. 
  • Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach. 
  • Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. 
  • Phase II study of amonafide in advanced pancreatic adenocarcinoma. 
  • Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. 
  • Phase II study of didemnin B in advanced colorectal cancer. 
  • Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. 
  • Phase II study of gemcitabine in advanced colorectal adenocarcinoma. 
  • Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma. 
  • Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. 
  • Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. 
  • Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. 
  • Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. 
  • Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. 
  • Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of curcumin in patients with advanced pancreatic cancer. 
  • Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. 
  • Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. 
  • Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Phase II trial of intravenous melphalan in advanced colorectal carcinoma. 
  • Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. 
  • Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma. 
  • Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. 
  • Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. 
  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. 
  • Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. 
  • Photosensitizing action of isomeric zinc N-methylpyridylporphyrins in human carcinoma cells. 
  • Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. 
  • Pitfalls in avoiding operation for autoimmune pancreatitis. 
  • Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. 
  • Platinum sensitivity in metastatic prostate cancer: does histology matter? 
  • Pleural effusion and renal cell carcinoma: an angiographic-pathologic correlation. 
  • Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. 
  • Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. 
  • Polymorphisms in excision repair cross-complementing group 4 (ERCC4) and susceptibility to primary lung cancer in a Chinese Han population. 
  • Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population. 
  • Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. 
  • Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population. 
  • Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer. 
  • Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? 
  • Possible mechanism for seeding of tumor during radical prostatectomy. 
  • Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Postfreeze viability of human epithelial carcinoma cells in quaternary solutions. 
  • Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. 
  • Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. 
  • Potentially functional polymorphisms in the CASP7 gene contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. 
  • Potentially functional variants of PLCE1 identified by GWASs contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. 
  • Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma. 
  • Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. 
  • Predictors of extracapsular extension and positive margins in African American and white men. 
  • Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study. 
  • Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). 
  • Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. 
  • Prenatal diethylstilbestrol exposure and human genital tract abnormalities. 
  • Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. 
  • Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. 
  • Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. 
  • Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. 
  • Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. 
  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. 
  • Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. 
  • Preoperative concurrent chemotherapy and radiotherapy in rectal cancer patients. 
  • Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. 
  • Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. 
  • Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. 
  • Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. 
  • Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. 
  • Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered? 
  • Preoperative radiotherapy for rectal cancer: benefits and controversies. 
  • Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. 
  • Prevalence of pulmonary atypical alveolar cell hyperplasia in an autopsy population: a study of 100 cases. 
  • Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. 
  • Primary adenocarcinoma of pigmented ciliary epithelium in a phthisical eye. 
  • Primary adenocarcinoma of the gallbladder presenting as primary gynecologic malignancy: a report of two cases. 
  • Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. 
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. 
  • Primary intranasal Fusarium infection. Potential for confusion with rhinocerebral zygomycosis. 
  • Primary non-urachal adenocarcinoma of the bladder. 
  • Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. 
  • Primary rectal adenocarcinoma presenting as a giant perianal mass mimicking giant condyloma of Buschke-Lowenstein. 
  • Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Prior tonsillectomy is associated with an increased risk of esophageal adenocarcinoma. 
  • Prognosis of patients with stage D1 prostatic adenocarcinoma. 
  • Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. 
  • Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. 
  • Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. 
  • Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. 
  • Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. 
  • Prognostic indicators for survival in stage I carcinoma of the lung: a histologic study of 47 surgically resected cases. 
  • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. 
  • Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. 
  • Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. 
  • Prognostic significance of the highest peripancreatic lymph node in biliary tract adenocarcinoma. 
  • Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer. 
  • Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. 
  • Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. 
  • Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma. 
  • Prospective phase I trial of conservative management of low rectal lesions. 
  • Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. 
  • Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. 
  • Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. 
  • Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. 
  • Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains. 
  • Prostate cancer, version 2.2014. 
  • Prostate cancer. 
  • Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. 
  • Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. 
  • Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. 
  • Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. 
  • Prostatic malignancy. 
  • Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. 
  • Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. 
  • Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. 
  • Pylorus-preserving pancreatoduodenectomy. A clinical and physiologic appraisal. 
  • Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. 
  • Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy. 
  • Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. 
  • Quantitative laser scanning confocal autofluorescence microscopy of normal, premalignant, and malignant colonic tissues. 
  • RARP in high-risk prostate cancer: use of multi-parametric MRI and nerve sparing techniques. 
  • RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. 
  • RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. 
  • RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. 
  • Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. 
  • Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. 
  • Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. 
  • Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. 
  • Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. 
  • Radical perineal prostatectomy. 
  • Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. 
  • Radical prostatectomy in stage A prostatic adenocarcinoma. 
  • Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. 
  • Radical prostatectomy: anatomical predictors of success or failure. 
  • Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. 
  • Radical surgery versus radiotherapy for adenocarcinoma of the prostate. 
  • Radioisotope bone scanning characteristics of metastatic skeletal deposits of prostatic adenocarcinoma. 
  • Radiologic findings of bronchogenic carcinoma with pulmonary metastases at presentation. 
  • Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation. 
  • Radiosensitive orbital metastasis as presentation of occult colonic adenocarcinoma. 
  • Radiotherapy following radical prostatectomy. 
  • Radiotherapy for locally recurrent prostate cancer. 
  • Radiotherapy versus surgery for localized prostatic cancer. 
  • Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. 
  • Randomized clinical trials in pancreatic adenocarcinoma. 
  • Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). 
  • Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. 
  • Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. 
  • Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. 
  • Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 
  • Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 
  • Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. 
  • Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. 
  • Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. 
  • Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. 
  • Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. 
  • Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis. 
  • Rare Coexistance of Ileal Diverticulosis, Crohn's Disease and Small Bowel Adenocarcinoma: Report of a Case. 
  • Rb and p16INK4a expression in resected non-small cell lung tumors. 
  • Reassessing the diagnostic yield of saturation biopsy of the prostate. 
  • Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix. 
  • Rectothecal Fistula Secondary to a Tailgut Cyst With Malignant Transformation: An Abnormal Connection and Unusual Pathology. 
  • Rectourethral fistula after combination radiotherapy for prostate cancer. 
  • Rectourethral fistulas in the cancer survivor. 
  • Recurrent tumor after resection of hepatic metastases from colorectal carcinoma: location and time of discovery as determined by CT. 
  • Reduced MFAP5 expression in stroma of gallbladder adenocarcinoma and its potential diagnostic utility. 
  • Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. 
  • Reducing hospital morbidity and mortality following esophagectomy. 
  • Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. 
  • Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens. 
  • Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. 
  • Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. 
  • Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1. 
  • Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. 
  • Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. 
  • Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients. 
  • Relationship between race and interval to treatment in endometrial cancer. 
  • Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. 
  • Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. 
  • Renal carcinosarcoma. Ultrastructure and transplantation into athymic mice. 
  • Renal metastasis of adenocarcinoma of the lung: massive hematuria managed by therapeutic embolization. 
  • Renal oncocytosis presenting in childhood: a case report. 
  • Renal tubular carcinoma; animal model: chemically induced renal tubular carcinoma in rats. 
  • Reply to F. Valcamonico et al. 
  • Reply to Moris et al. 
  • Reply: To PMID 23063200. 
  • Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. 
  • Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. 
  • Resected irradiated rectal cancers: Are twelve lymph nodes really necessary in the era of neoadjuvant therapy? 
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. 
  • Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). 
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). 
  • Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. 
  • Retinoic acid modulation of alpha(1-->2) fucosyltransferase activity and sensitivity of tumor cells to LAK-mediated cytotoxicity. 
  • Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Risk factors for perineal seeding of prostate cancer after needle biopsy. 
  • Risk of exogenous estrogen therapy and endometrial cancer. 
  • Role of Adjuvant Radiotherapy in Locally Advanced Colonic Carcinoma in the Modern Chemotherapy Era. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Role of closed-needle biopsy in the diagnosis of malignant mesothelioma of the pleura. 
  • Role of hormones including diethylstibestrol (DES) in the pathogenesis of cervical and vaginal intraepithelial neoplasia. 
  • Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield. 
  • Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. 
  • Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. 
  • S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. 
  • SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. 
  • SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. 
  • Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. 
  • Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. 
  • Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. 
  • Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. 
  • Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. 
  • Scanning and transmission electron microscopy of human prostatic acinar cells. 
  • Scanning electron microscopy of hyperplastic and neoplastic human prostate. 
  • Sclerosing mesenteritis involving the pancreas: a mimicker of pancreatic cancer. 
  • Secretory IgA and mucin-mediated biofilm formation by environmental strains of Escherichia coli: role of type 1 pili. 
  • Seduced by dose? 
  • Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. 
  • Seminal vesicle intraepithelial involvement by prostate cancer: putative mechanism and clinicopathological significance. 
  • Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. 
  • Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 
  • Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. 
  • Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development. 
  • Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. 
  • Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. 
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. 
  • Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. 
  • Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. 
  • Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. 
  • Short communication: CT-MRI image fusion for 3D conformal prostate radiotherapy: use in patients with altered pelvic anatomy. 
  • Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. 
  • Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. 
  • Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. 
  • Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. 
  • Single-Center Experience with Magnetic Retraction in Colorectal Surgery. 
  • Skin metastases confined to a field of previous irradiation. Report of two cases and review of the literature. 
  • Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Small cell carcinoma of the prostate: an immunohistochemical study. 
  • Small neuroendocrine lesions in intrathoracic lymph nodes of patients with primary lung adenocarcinoma: real metastasis? 
  • Smoking, Helicobacter Pylori Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea. 
  • Smoking-related genomic signatures in non-small cell lung cancer. 
  • Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. 
  • Soft tissue tumors of the prostate: a review. 
  • Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. 
  • Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma. 
  • Spectroscopic optical coherence tomography for classification of colorectal cancer in a mouse model. 
  • Sphincter-sparing treatment for distal rectal adenocarcinoma. 
  • Spontaneously acquired anti-factor VIII antibodies: report of a patient with adenocarcinoma of the prostate. 
  • Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? 
  • Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. 
  • Staging of esophageal cancer by EUS: staging accuracy revisited. 
  • Staging of pancreatic cancer before and after neoadjuvant chemoradiation. 
  • Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. 
  • Staging techniques for lung cancer. 
  • Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. 
  • Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. 
  • Statistical analysis of cytologic features useful in separation of metastatic urothelial carcinoma from other metastatic epithelial malignancies. 
  • Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. 
  • Stratification of risk factors in renal cell carcinoma. 
  • Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure. 
  • Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. 
  • Structural anomalies of the cervix and vagina in women enrolled in the Diethylstilbestrol Adenosis (DESAD) Project. 
  • Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. 
  • Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. 
  • Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. 
  • Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer. 
  • Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. 
  • Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. 
  • Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone. 
  • Surgical management of high-risk, localized prostate cancer. 
  • Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? 
  • Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy. 
  • Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. 
  • Surgical validation of angiographic studies of renal lesions. 
  • Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. 
  • Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. 
  • Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. 
  • Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). 
  • Sweet's syndrome with neurologic manifestations in a patient with esophageal adenocarcinoma: case report and review of the literature. 
  • Synchronous primary perianal Paget's disease and rectal adenocarcinoma: report of a hitherto undescribed phenomenon. 
  • Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. 
  • Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. 
  • Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. 
  • Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? 
  • Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. 
  • T1a Versus T1b Differentiated Thyroid Cancers: Do We Need to Make the Distinction? 
  • TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. 
  • TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. 
  • Tagging single nucleotide polymorphisms in MBD4 are associated with risk of lung cancer in a Chinese population. 
  • Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas. 
  • Technical considerations in radiation therapy for gastroesophageal junction cancer. 
  • Ten years of respiratory cytopathology at Duke University Medical Center. II. The cytopathologic diagnosis of lung cancer during the years 1970 to 1974, with a comparison between cytopathology and histopathology in the typing of lung cancer. 
  • Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. 
  • The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. 
  • The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. 
  • The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. 
  • The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. 
  • The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? 
  • The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. 
  • The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. 
  • The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. 
  • The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. 
  • The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. 
  • The Impact of Extended Delayed Surgery for Indolent Lung Cancer or Part-Solid Ground Glass Nodules. 
  • The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. 
  • The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. 
  • The Pseudocavitation Sign of Lung Adenocarcinoma: A Distinguishing Feature and Imaging Biomarker of Lepidic Growth. 
  • The Ras-related protein AGS1/RASD1 suppresses cell growth. 
  • The Relationship Between Lymph Node Ratio and Survival Benefit With Adjuvant Chemotherapy in Node-positive Esophageal Adenocarcinoma. 
  • The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. 
  • The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. 
  • The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. 
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 
  • The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration. 
  • The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. 
  • The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). 
  • The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. 
  • The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. 
  • The effect of rate of heating or cooling prior to heating on tumor and normal tissue microcirculatory blood flow. 
  • The effects of hyperoxic and hypercarbic gases on tumour blood flow. 
  • The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. 
  • The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study. 
  • The expression of Claudin-4 in gastric cancer tissue: A single center experience. 
  • The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 
  • The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy? 
  • The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). 
  • The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma. 
  • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. 
  • The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. 
  • The investigation on the location effect of external markers in respiratory-gated radiotherapy. 
  • The management of clinically localized prostate cancer. A summary of the Consensus Statement of the National Institutes of Health. 
  • The management of tumors of the ampulla of Vater by local resection. 
  • The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. 
  • The multidisciplinary approach to adenocarcinoma of the prostate at Moore Regional Hospital. 
  • The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. 
  • The natural progression of adenocarcinoma of the epididymis. 
  • The need for standardized pathologic staging of pancreaticoduodenectomy specimens. 
  • The novel triad of dorsal agenesis of the pancreas with concurrent pancreatic ductal adenocarcinoma and nonalcoholic chronic calcific pancreatitis: a case series and review of the literature. 
  • The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. 
  • The nucleolar localization domain of the catalytic subunit of human telomerase. 
  • The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. 
  • The p53 tumor suppressor gene frequently is altered in gynecologic cancers. 
  • The pathologic features and behavior of endometrial carcinoma associated with exogenous estrogen administration. 
  • The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. 
  • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. 
  • The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. 
  • The role of individualized treatment in patients with oesophageal cancer: mind the patient and not only the disease. 
  • The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. 
  • The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. 
  • The side of the primary tumor affects overall survival in colon adenocarcinoma: an analysis of the national cancer database. 
  • The significance of adenosis and clear-cell adenocarcinoma of the genital tract in young females. 
  • The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. 
  • The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. 
  • Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. 
  • Thioredoxin-mediated denitrosylation regulates cytokine-induced nuclear factor κB (NF-κB) activation. 
  • Thoracic empyema associated with recurrent colon cancer: report of a case and review of the literature. 
  • Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report. 
  • Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). 
  • Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. 
  • Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. 
  • Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. 
  • Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. 
  • Topographic relation of cervical ectropion and vaginal adenosis to clear cell adenocarcinoma. 
  • Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer. 
  • Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. 
  • Transhiatal esophagogastrectomy for an isolated ovarian cancer metastasis to the esophagus. 
  • Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. 
  • Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. 
  • Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. 
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. 
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. 
  • Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. 
  • Triphasic contrast enhanced CT simulation with bolus tracking for pancreas SBRT target delineation. 
  • Tuboovarian abscess in postmenopausal women. 
  • Tumor Size, Histology, and Survival After Stereotactic Ablative Radiotherapy and Sublobar Resection in Node-negative Non-small Cell Lung Cancer. 
  • Tumor marker expression is predictive of survival in patients with esophageal cancer. 
  • Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma. 
  • Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. 
  • Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. 
  • Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. 
  • Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. 
  • U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. 
  • Ulex europeus agglutinin I-reactive high molecular weight glycoproteins of adenocarcinoma of distal colon and rectum and their possible relationship with metastatic potential. 
  • Ultrasonographic findings of small hypernephroma associated with renal cyst. 
  • Ultrastructural features of diffuse malignant mesotheliomas. 
  • Ultrastructure of 16 cases of clear cell adenocarcinoma of the vagina and cervix in young women. 
  • Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. 
  • Unknown primary tumors metastatic to liver. 
  • Unusual finding in a patient with pancreas divisum and abdominal pain. 
  • Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. 
  • Update on transrectal ultrasound-guided needle biopsy of the prostate. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. 
  • Urea as a recovery marker for quantitative assessment of tumor interstitial solutes with microdialysis. 
  • Ureteral reimplantation for inadvertent ureteral injury during radical perineal prostatectomy. 
  • Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. 
  • Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. 
  • Use of trastuzumab in the treatment of metastatic endometrial cancer. 
  • Using ordinal logistic regression to estimate the likelihood of colorectal neoplasia. 
  • Uterine Neoplasms. Clinical Practice Guidelines in Oncology. 
  • Utility of a prognostic nomogram designed for gastric cancer in predicting outcome of patients with R0 resected duodenal adenocarcinoma. 
  • Vaginal adenosis and other diethylstilbestrol-related abnormalities. 
  • Vaginal and cervical abnormalities, including clear-cell adenocarcinoma, related to prenatal exposure to stilbestrol. 
  • Vaginal epithelial changes in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) project. 
  • Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. 
  • Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. 
  • Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. 
  • Variant prostate carcinoma and elevated serum CA-125. 
  • Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. 
  • Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations. 
  • Vascular surgery collaboration during pancreaticoduodenectomy with vascular reconstruction. 
  • Villoglandular adenocarcinoma of the cervix: a case report. 
  • Vincristine, bleomycin, methotrexate, 5-fluorouracil, and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. 
  • Whole-genome reconstruction and mutational signatures in gastric cancer. 
  • Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. 
  • With widespread adoption of MIS colectomy for colon cancer, does hospital type matter? 
  • Words of wisdom. Re: Tracking the clonal origin of lethal prostate cancer. 
  • X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model. 
  • [Experimental studies on human lung cancer gene-therapy with HSV-TK/GCV system]. 
  • [GIPC: a new target for therapy in pancreatic adenocarcinoma?]. 
  • [Intraportal injection of specific monoclonal antibody in nude mice with liver metastasis]. 
  • [Metastatic sites of colonic adenocarcinoma in the ORL system: 2 cases]. 
  • [Murine Doube Minute 2 oncogene inhibited apoptosis induced by retroviral-mediated wild-type p53]. 
  • [Studies on MDM2 oncogene expression and its effect on pancreatic carcinoma cells]. 
  • [The effect of adenovirus-mediated wild-type p53 expression on the growth of human pancreatic carcinoma cell line cells]. 
  • [The inhibitory effect of combined treatment of TNF alpha and antisense oligodeoxynucleotides on the growth of human pancreatic carcinoma cell line cells]. 
  • bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. 
  • hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. 
  • microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). 
  • p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. 
  • p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. 
  • p53 overexpression in advanced-stage endometrial adenocarcinoma. 
  • p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). 
  • p53lyn and p56lyn: a new signaling pathway in human endometrium and endometrial adenocarcinomas. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Driehuys, Bastiaan, Professor of Radiology, Biomedical Engineering
  • Garman, Katherine Schuver, Associate Professor of Medicine, Medicine, Gastroenterology
  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Hogan, Brigid L. M., Research Professor of Cell Biology, Cell Biology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Routh, Jonathan Charles, Paul H. Sherman, M.D. Distinguished Associate Professor of Surgery, Pediatrics
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society